Hill-McManus D, Lai Y, Bensimon AG, Young J, et al. Cost-effectiveness of perioperative pembrolizumab plus enfortumab vedotin for cisplatin-ineligible or cisplatin-declining patients with muscle-invasive bladder cancer in the United States. J Med Econ 2026;29:2161-2176.
PMID: 42610318